Quarterly report · Q2
4570.TEDINET S100PKP5
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥293m | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥648m | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥254m | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | −¥55m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | −¥137m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | −¥130m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥243m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥188m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥132m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥195m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥136m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥259m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥199m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥136m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | −¥199m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥1.6bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥1.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.7bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥329m | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥337m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.2bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥1.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥406m | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥508m | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥341m | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥449m | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥546m | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥552m | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥51m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥93m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥100m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥64m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥156m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥39m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥3m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥144m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥132m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-14.62 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.29 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-27.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-21.4 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-9.51 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 78.9% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.8% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 25
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥8m |
| jpcrp040300-q2r_E00986-000Gene Recombination Silkworm Developmentreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥41m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥291m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥291m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥6m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥293m |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥293m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | −¥55m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | ¥480,000 |
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥10m |
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥10m |
| jpcrp040300-q2r_E00986-000Cosmeticsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥5m |
| jpcrp040300-q2r_E00986-000Gene Recombination Silkworm Developmentreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥53m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥247m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥244m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3m |
| jpcrp040300-q2r_E00986-000Immunity Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥79m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥257m |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥254m |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | −¥137m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 431
| Item | Context | Value | Unit |
|---|---|---|---|
| Other net inv cf | Prior1YTDDuration | － | JPY |
| Other net inv cf | CurrentYTDDuration | 50000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -39000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -63950000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 100000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | 5000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 40000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -8000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -2004000 | JPY |
| Other net fin cf | Prior1YTDDuration | － | JPY |
| Other net fin cf | CurrentYTDDuration | 0 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 132000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 2995000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 816000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 3191000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -5687000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -108389000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 552022000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 449184000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 546335000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 340795000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 4447000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 5686000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 98086000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 87966000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00986-000ImmunityRelatedReportableSegmentMember | 244062000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00986-000GeneRecombinationSilkwormDevelopmentReportableSegmentMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00986-000CosmeticsReportableSegmentsMember | 9931000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 253993000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 253993000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00986-000ImmunityRelatedReportableSegmentMember | 3222000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00986-000GeneRecombinationSilkwormDevelopmentReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00986-000CosmeticsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 3222000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -3222000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00986-000ImmunityRelatedReportableSegmentMember | 247284000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00986-000GeneRecombinationSilkwormDevelopmentReportableSegmentMember | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00986-000CosmeticsReportableSegmentsMember | 9931000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 257216000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -3222000 | JPY |
| Net sales | Prior1YTDDuration | 253993000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00986-000ImmunityRelatedReportableSegmentMember | -79350000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00986-000GeneRecombinationSilkwormDevelopmentReportableSegmentMember | -52616000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00986-000CosmeticsReportableSegmentsMember | -5033000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | -137000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | 480000 | JPY |
| Operating income | Prior1YTDDuration | -136520000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |